Jackson News Reporter

Non-Alcoholic Steatohepatitis (NASH) Marketed and Emerging Pipeline Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

 Breaking News
  • No posts were found

Non-Alcoholic Steatohepatitis (NASH) Marketed and Emerging Pipeline Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

March 01
00:08 2023
Non-Alcoholic Steatohepatitis (NASH) Marketed and Emerging Pipeline Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 150+ pipeline drugs in the Non-Alcoholic Steatohepatitis (NASH) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Non-Alcoholic Steatohepatitis Market. 

The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis

Non-Alcoholic Steatohepatitis (NASH) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Non-Alcoholic Steatohepatitis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Non-Alcoholic Steatohepatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

Non-Alcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal


Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the Non-Alcoholic Steatohepatitis Therapeutic Segment @


Non-Alcoholic Steatohepatitis (NASH) Therapeutics Assessment

There are approx. 130+ key companies developing therapies for Non-Alcoholic Steatohepatitis. Currently, Madrigal Pharmaceuticals is leading the therapeutics market with its Non-Alcoholic Steatohepatitis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market Include:

Akero Therapeutics, Albireo Pharma, Altimmune, Inc., Amgen, ARTham Therapeutics, Ascletis, AstraZeneca, Bird Rock Bio, Boston Pharmaceuticals, Bristol-Myers Squibb, Cascade Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cirius Therapeutics, DURECT Corporation, Enanta Pharmaceuticals, Enzychem Lifesciences, Galecto Biotech, Gmax Biopharm, GSK plc., Guangdong Zhongsheng Pharmaceutical, Hepion Pharmaceuticals, Ildong Pharmaceutical, Ildong Pharmaceutical, InorbitTX, Ionis Pharmaceuticals, J2H Biotech, LG Chem Life sciences, Liminal BioSciences, Madrigal Pharmaceuticals, Melior Pharmaceuticals, Merck Sharp & Dohme LLC, NorthSea Therapeutics, Palobiofarma, Pharmaxis, Pliant Therapeutics, Rivus Pharmaceuticals, Sciwind Biosciences, SCOHIA PHARMA, TaiwanJ Pharmaceuticals, Thoth Science, Tiziana Life Sciences, TransThera Biosciences, Viking Therapeutics, and many others.

Non-Alcoholic Steatohepatitis Emerging and Marketed Drugs Covered in the Report Include:

  • Resmetirom: Madrigal Pharmaceuticals

  • MSDC-0602K: Cirius Therapeutics

  • ION224: Ionis Pharmaceuticals

  • HU 6: Rivus Pharmaceuticals

  • HTD 1801: HighTide Biopharma

  • EDP-305: Enanta Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Non-Alcoholic Steatohepatitis Current Treatment Patterns

4. Non-Alcoholic Steatohepatitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Non-Alcoholic Steatohepatitis Late Stage Products (Phase-III)

7. Non-Alcoholic Steatohepatitis Mid-Stage Products (Phase-II)

8. Non-Alcoholic Steatohepatitis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Alcoholic Steatohepatitis Discontinued Products

13. Non-Alcoholic Steatohepatitis Product Profiles

14. Key Companies in the Non-Alcoholic Steatohepatitis Market

15. Key Products in the Non-Alcoholic Steatohepatitis Therapeutics Segment

16. Dormant and Discontinued Products

17. Non-Alcoholic Steatohepatitis Unmet Needs

18. Non-Alcoholic Steatohepatitis Future Perspectives

19. Non-Alcoholic Steatohepatitis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 



Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services and Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/